Full Press Release Details
Purple Biotech Announces
Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting
REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd.
("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies
that seek to overcome tumor immune evasion and drug resistance, today announced upcoming poster presentations including one for CM24
in the treatment of pancreatic cancer, and two for NT219 in the treatment of colorectal and head and neck cancers, at the 2025 American
Association for Cancer Research Meeting (2025 AACR), scheduled to take place from April 25th to April 30th in Chicago. Presentation details
Abstract Title: Final analysis of the randomized
Phase 2 cohort of CM24 with nivolumab and chemotherapy in pancreatic cancer & potential serum biomarkers
Session Title: Liquid
Biopsy: Circulating Nucleic Acids 4 / Predictive Biomarkers 1
Session Date and Time:
Wednesday, April 30, 9:00 a.m. - 12:00 p.m.
Abstract Title: APC-loss as a potential
biomarker for NT219 treatment in colorectal cancer (CRC)
Session Title: Molecular Classification
of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes
Session Date and Time: Sunday,
April 27, 2:00 - 5:00 p.m.
Abstract Title: NT219 overcomes immune evasion-resistant
mechanisms in head and neck squamous cell carcinoma (HNSCC)
Session Title: Novel Drug Resistance
Session Date and Time: Monday,
April 28, 2:00 - 5:00 p.m.
About Purple Biotech
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage
company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Company's oncology pipeline
includes CM24, NT219, and CAPTN-3. CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion and
survival through multiple pathways. CEACAM1 on tumor cells, immune cells and neutrophils extracellular traps is a novel target for the
treatment of multiple cancer indications. As proof of concept of these novel pathways, the Company completed a Phase 2 study for the treatment
of pancreatic ductal adenocarcinoma (PDAC) with CM24 as a combination therapy with the anti-PD-1 checkpoint inhibitor nivolumab and chemotherapy,
demonstrating clear and consistent improvement across all efficacy endpoints and the identification of two potential serum biomarkers.
NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. A Phase 1 dose escalation study was concluded
as a monotherapy and in combination with cetuximab, in which NT219 demonstrated anti-tumor activity in combination with cetuximab in second-line
patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). The Company is advancing NT219 into
a Phase 2 study in collaboration with the University of Colorado, to treat R/M SCCHN patients in combination with cetuximab or pembrolizumab.
The Company is advancing CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which engage both T cells
and NK cells to induce a strong, localized immune response within the tumor microenvironment. The cleavable capping technology confines
the compound's therapeutic activity to the local tumor microenvironment, thereby potentially increasing the anticipated therapeutic window
in patients. The third arm specifically targets the Tumor Associated Antigen (TAA). The technology presents a novel mechanism of action
by unleashing both innate and adaptive immune systems to mount an optimal anti-tumoral immune response. IM1240 is the first tri-specific
antibody in development that targets the 5T4 antigen, which is expressed in a variety of solid tumors and is associated with advanced
disease, increased invasiveness, and poor clinical outcomes. The Company's corporate headquarters are located in Rehovot, Israel. For
more information, please visit https://purple-biotech.com/.
Forward-Looking Statements and Safe Harbor
Certain statements in this press release that are forward-looking and
not statements of historical fact are forwardlooking statements within the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements that are not statements of
historical fact, and may be identified by words such as "believe", "expect", "intend", "plan",
"may", "should", "could", "might", "seek", "target", "will", "project",
"forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable
words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these
forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations,
beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many
of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements
to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements.
Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies and
objectives of management for future operations; product development for NT219, CM24 and IM1240; the process by which such early stage
therapeutic candidates could potentially lead to an approved drug product is long and subject to highly significant risks, particularly
with respect to a joint development collaboration; the fact that drug development and commercialization involves a lengthy and expensive
process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; the expense, length,
progress and results of any clinical trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical
industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting
actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment
and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception
to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained
by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain
and defend issued patents; the commencement of any patent interference or infringement action against our patents, and our ability to
prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation,
and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2024
and in our other filings with the U.S. Securities and Exchange Commission ("SEC"), including our cautionary discussion of risks
and uncertainties under "Risk Factors" in our Registration Statements and Annual Reports. These are factors that we believe
could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely
affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention
or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of
new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional
disclosures we make in our reports to the SEC, which are available on the SEC's website, https://www.sec.gov.